As noted above, MYCN-amplified neuroblastoma has a worse response to therapy and higher rate of both de novo drug resistance, treatment associated drug resistance, and recurrence compared to MYCN non-amplified tumors [8, 35]. Here, MYCN is linked to neuroblastoma.